VivoSeq
Other

Biological Availability

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Biological Availability is an early-stage landscape with 0 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06877702·85 enrolled
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06955741·46 enrolled
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06027437·21 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)